Teva gets FDA nod for deferoxamine mesylate for Injection USP

The US Food and Drug Administration has granted approval for Teva Pharmaceutical Industries' ANDA for Deferoxamine Mesylate for Injection USP, 500 mg/vial and 2 g/vial. Shipment of this product will begin immediately. Teva's Deferoxamine Mesylate for Injection is the AP-rated generic equivalent of Novartis' Desferal for Injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias. Total annual sales of Deferoxamine Mesylate for Injection are approximately $43 million.